


5

4

3 2 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

1991


5

4

3


2

1




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

1992




Topic Key:


1. Drug Metabolism	11. Drug Failures	21. Treatment
2. ARV1	12. Neuropathy	22. Genetic Variability
3. Hepatitis	13. Survival	23. Transmission1
4. Replication Blocking	14. Methods1	24. Testing Assays
5. Animal Models	15. Clinical Trials	25. Vaccine
6. Africa	16. PMTCT	26. Prevalence
7. Methods2	17. Opportunistic Infections	27. Symptomatology
8. ARV3	18. Immunity	28. Oncology
9. Transmission3	19. ARV2	29. PCR
10. Race & Gender	20. Cost Effectiveness	30. Transmission2



1993



1994



Topic Key:		
1. Drug Metabolism	11. Drug Failures	21. Treatment
2. ARV1	12. Neuropathy	22. Genetic Variability
3. Hepatitis	13. Survival	23. Transmission1
4. Replication Blocking	14. Methods1	24. Testing Assays
5. Animal Models	15. Clinical Trials	25. Vaccine
6. Africa	16. PMTCT	26. Prevalence
7. Methods2	17. Opportunistic Infections	27. Symptomatology
8. ARV3	18. Immunity	28. Oncology
9. Transmission3	19. ARV2	29. PCR
10. Race & Gender	20. Cost Effectiveness	30. Transmission2

7 6 5

4

3

2

1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

1995

8 7 6 5

4

3


2

1




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30


1996




Topic Key:		
1. Drug Metabolism	11. Drug Failures	21. Treatment
2. ARV1	12. Neuropathy	22. Genetic Variability
3. Hepatitis	13. Survival	23. Transmission1
4. Replication Blocking	14. Methods1	24. Testing Assays
5. Animal Models	15. Clinical Trials	25. Vaccine
6. Africa	16. PMTCT	26. Prevalence
7. Methods2	17. Opportunistic Infections	27. Symptomatology
8. ARV3	18. Immunity	28. Oncology
9. Transmission3	19. ARV2	29. PCR
10. Race & Gender	20. Cost Effectiveness	30. Transmission2



1997



1998



Topic Key:

1. Drug Metabolism	11. Drug Failures	21. Treatment
2. ARV1	12. Neuropathy	22. Genetic Variability
3. Hepatitis	13. Survival	23. Transmission1
4. Replication Blocking	14. Methods1	24. Testing Assays
5. Animal Models	15. Clinical Trials	25. Vaccine
6. Africa	16. PMTCT	26. Prevalence
7. Methods2	17. Opportunistic Infections	27. Symptomatology
8. ARV3	18. Immunity	28. Oncology
9. Transmission3	19. ARV2	29. PCR
10. Race & Gender	20. Cost Effectiveness	30. Transmission2


8 7 6 5

4

3

2

1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

1999

8 7

6


5

4

3


2

1




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30


2000




Topic Key:		
1. Drug Metabolism	11. Drug Failures	21. Treatment
2. ARV1	12. Neuropathy	22. Genetic Variability
3. Hepatitis	13. Survival	23. Transmission1
4. Replication Blocking	14. Methods1	24. Testing Assays
5. Animal Models	15. Clinical Trials	25. Vaccine
6. Africa	16. PMTCT	26. Prevalence
7. Methods2	17. Opportunistic Infections	27. Symptomatology
8. ARV3	18. Immunity	28. Oncology
9. Transmission3	19. ARV2	29. PCR
10. Race & Gender	20. Cost Effectiveness	30. Transmission2




2001




2002




Topic Key:		
1. Drug Metabolism	11. Drug Failures	21. Treatment
2. ARV1	12. Neuropathy	22. Genetic Variability
3. Hepatitis	13. Survival	23. Transmission1
4. Replication Blocking	14. Methods1	24. Testing Assays
5. Animal Models	15. Clinical Trials	25. Vaccine
6. Africa	16. PMTCT	26. Prevalence
7. Methods2	17. Opportunistic Infections	27. Symptomatology
8. ARV3	18. Immunity	28. Oncology
9. Transmission3	19. ARV2	29. PCR
10. Race & Gender	20. Cost Effectiveness	30. Transmission2




2003




2004




Topic Key:		
1. Drug Metabolism	11. Drug Failures	21. Treatment
2. ARV1	12. Neuropathy	22. Genetic Variability
3. Hepatitis	13. Survival	23. Transmission1
4. Replication Blocking	14. Methods1	24. Testing Assays
5. Animal Models	15. Clinical Trials	25. Vaccine
6. Africa	16. PMTCT	26. Prevalence
7. Methods2	17. Opportunistic Infections	27. Symptomatology
8. ARV3	18. Immunity	28. Oncology
9. Transmission3	19. ARV2	29. PCR
10. Race & Gender	20. Cost Effectiveness	30. Transmission2




2005




2006




Topic Key:		
1. Drug Metabolism	11. Drug Failures	21. Treatment
2. ARV1	12. Neuropathy	22. Genetic Variability
3. Hepatitis	13. Survival	23. Transmission1
4. Replication Blocking	14. Methods1	24. Testing Assays
5. Animal Models	15. Clinical Trials	25. Vaccine
6. Africa	16. PMTCT	26. Prevalence
7. Methods2	17. Opportunistic Infections	27. Symptomatology
8. ARV3	18. Immunity	28. Oncology
9. Transmission3	19. ARV2	29. PCR
10. Race & Gender	20. Cost Effectiveness	30. Transmission2



2007



2008



Topic Key:		
1. Drug Metabolism	11. Drug Failures	21. Treatment
2. ARV1	12. Neuropathy	22. Genetic Variability
3. Hepatitis	13. Survival	23. Transmission1
4. Replication Blocking	14. Methods1	24. Testing Assays
5. Animal Models	15. Clinical Trials	25. Vaccine
6. Africa	16. PMTCT	26. Prevalence
7. Methods2	17. Opportunistic Infections	27. Symptomatology
8. ARV3	18. Immunity	28. Oncology
9. Transmission3	19. ARV2	29. PCR
10. Race & Gender	20. Cost Effectiveness	30. Transmission2